A recent preliminary study by the United States Preventive Services Working Group (USPSTF) determined that performing high-risk human papilomavirus (VPH) detection tests every five years is the most recommendable strategy for detecting human papiloma virus (VPH) uterus in women starting from the age of 30. This focus includes allowing women to recognize their own exhibits for testing, which represents a significant advance in the detection of this infirmity.
Traditionally, testing for cervical cancer was done through cervical cytology, commonly known as the Papanicolaou test. This procedure involves collecting cells from the cervix for analysis for signs of cancer. However, the new focus highlights the importance of VPH detection as the primary method, as most cases of cervical cancer are attributable to this virus. The VPH test involves collecting a vaginal mask that is analyzed to identify the presence of high-risk strains that can lead to the development of cancer.
Dr. Esa Davis, a member of the working group and professor of public health at the University of Maryland, noted that the VPH trial offers the best balance between benefits and risks in detecting uterine breast cancer, suggesting that it should be it is the first option available for women between 30 and 65 years old. Furthermore, the inclusion of the automatic viewing option presents itself as an attractive alternative for those who do not feel comfortable consulting a medical professional.
When the VPH test is not available, the working group recommends performing the Papanicolaou test or a combination of two tests. Although the VPH test is considered more effective, the other two options continue to be valid and effective in cancer detection.
The update of these recommendations does not imply that the Papanicolaou test is damaged, but that the VPH test is more effective in identifying cervical cancer in women between 30 and 65 years of age. For women aged 20 to 39, it is recommended to continue with cervical cytology tests every three years.
The draft recommendation is in preliminary stages and will be available for public comment until January 13. The USPSTF is a panel of experts that issues recommendations that impact medical practice and security coverage decisions. The Sociedad Estadoundense del Cáncer has also responded to the VPH test as part of a uterine cancer detection program, reporting that it is more effective for its prevention than the Papanicolaou test carried out in isolated form.
Dr. Robert Smith, senior vice president of temporary cancer detection science at the State Cancer Society, said he expects to review the USPSTF's recommendations, because temporary detection is crucial. Cervical cancer is one of the most preventable and treatable types of cancer and it is essential that women have regular screening tests.
It is estimated that approximately 80% of people will get a VPH infection at some time in their lives. This virus, which includes more than 150 strains, is transmitted mainly by sexual contact and can cause warts, increasing the risk of several types of cancer, including cervical, anal, penile and oropharynx. While the presence of high-risk VPH does not mean a woman has cancer, it is critical to detect it early, as in most cases the virus clears itself naturally within two years.
The USPSTF's latest recommendation, dated 2018, suggests that women between the ages of 21 and 29 have cervical cytology tests every three years. For women ages 30 to 65, recommended options include cervical cytology tests every three years, VPH tests every five years, or a combination of the two. This new proposal continues to recommend not carrying out detection tests on women under the age of 21 or on those 65-year-olds who have had adequate tests in the past and who do not have a high cancer risk.
The importance of regular testing within the 21 to 65 age group cannot be understated, as temporary detection is key to the prevention and treatment of uterine breast cancer. Introducing automated testing of VPH views could broaden access to these tests, making it easier to detect more women.
In May, the FDA expanded approvals for VPH trials, allowing vaginal figures to be collected by their patients, which provides greater convenience and accessibility. This option may be attractive to those who prefer to avoid collection of exhibits by a health professional, which could lead to an increase in the number of women getting fulfilled.
The exhibit automaton offers a way to overcome the barriers some women face when trying to access medical attention. Dr. Davis' commitment to eliminating barriers is critical to ensuring that all women who qualify for trials feel motivated to pursue them. In making the process more accessible and convenient, if more women hopefully take advantage of the opportunity to have detection tests, this could result in a significant decrease in cases of uterine breast cancer.
Advancing advice and including more accessible options are important steps in improving women's health and preventing serious injuries. Temperature measurement is a key determinant of treatment outcome, and as awareness and evidence increases, the door to a healthier future opens for many women.
